A new antiviral medicine for chronic hepatitis B that aims for a complete cure
Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure
This project is creating a new medicine to help people with chronic hepatitis B achieve a lasting cure, rather than just controlling the infection.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Evrys Bio, LLC NIH-funded |
| Lab location | 1 site (Doylestown, United States) |
| Project ID | NIH-11141017 on NIH RePORTER |
What this research studies
Chronic hepatitis B can lead to serious liver problems, and current treatments often don't fully get rid of the virus. This project is working on a new type of antiviral medicine that targets a specific part of the body's own cells, called sirtuins, to fight the hepatitis B virus. Researchers believe this approach could lead to a "functional cure," meaning the virus would become undetectable and inactive in the body. The initial steps involve confirming how well this new medicine works in human liver cells and against different types of the virus.
Who could benefit from this research
Good fit: Patients with chronic hepatitis B infection who currently rely on treatments that only control the virus would be the ideal candidates for this future therapy.
Not a fit: Patients without chronic hepatitis B infection or those whose condition is already fully resolved would not benefit from this specific treatment.
Why it matters
Potential benefit: If successful, this medicine could offer a lasting cure for chronic hepatitis B, preventing severe liver disease for millions of people worldwide.
How similar studies have performed: The applicant has previously identified sirtuin modulators with broad antiviral activity, suggesting a promising, though still early-stage, approach.
Where this research is happening
Doylestown, United States
- Evrys Bio, LLC — Doylestown, United States (Active)
Researchers
- Principal investigator: Remiszewski, Stacy — Evrys Bio, LLC
- Study coordinator: Remiszewski, Stacy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.